Vergleich

Biotinylated Mouse LRRC15 / LIB Protein, His,Avitag™ Europäischer Partner

ArtNr LR5-M82E6-200ug
Hersteller ACROBiosystems
Menge 200 ug
Kategorie
Typ Proteins Recombinant
Format Powder
Specific against Mouse
Host HEK293
Konjugat/Tag Biotin, HIS, Avi
Purity 95%
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib
Lieferbar
Manufacturers Category
Protein / MABSol® Biotin Labeled Proteins
Description
Biotinylated Mouse LRRC15, His, Avitag (LR5-M82E6) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 536 (Accession # Q80X72-1).
Molecule
LRRC15
Exp Region
Tyr 22 - Gly 536
Storage
-20℃
Shipping
RT
Stability
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Molecular Weight
61.2 kDa
Characteristics
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 61.2 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
1.0 EU per μg
Buffer
PBS, pH7.4
Background
LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 200 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen